Standout Papers

Global Strategy for the Diagnosis, Management, and Preven... 2003 2026 2010 2018 9.2k
  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2012)
    Jørgen Vestbo, Suzanne S. Hurd et al. American Journal of Respiratory and Critical Care Medicine
  2. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18 (2003)
    Andreas Rembert Koczulla, Georges von Degenfeld et al. Journal of Clinical Investigation
  3. Treatable traits: toward precision medicine of chronic airway diseases (2016)
    Àlvar Agustí, Elisabeth H. Bel et al. European Respiratory Journal
  4. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD (2016)
    Jadwiga A. Wedzicha, Donald Banerji et al. New England Journal of Medicine
  5. Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD (2011)
    Claus Vogelmeier, Bettina Hederer et al. New England Journal of Medicine
  6. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease (2020)
    David Halpin, Gerard J. Criner et al. American Journal of Respiratory and Critical Care Medicine
  7. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision (2022)
    Bartolomé R. Celli, Leonardo M. Fabbri et al. American Journal of Respiratory and Critical Care Medicine
  8. COPD and multimorbidity: recognising and addressing a syndemic occurrence (2023)
    Leonardo M. Fabbri, Bartolomé R. Celli et al. The Lancet Respiratory Medicine
  9. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation (2024)
    Surya P. Bhatt, Klaus F. Rabe et al. New England Journal of Medicine
  10. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials (2025)
    Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine

Immediate Impact

3 by Nobel laureates 11 from Science/Nature 61 standout
Sub-graph 1 of 16

Citing Papers

Chronic obstructive pulmonary disease
2022 Standout
Allergen immunotherapy: past, present and future
2022 Standout
74 intermediate papers

Works of Claus Vogelmeier being referenced

Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET
2021
CYT003, a TLR9 agonist, in persistent allergic asthma – a randomized placebo‐controlled Phase 2b study
2015
and 17 more

Author Peers

Author Last Decade Papers Cites
Claus Vogelmeier 18049 9499 1322 2294 438 25.0k
Klaus F. Rabe 24923 17533 1019 4541 500 36.2k
Robert A. Stockley 15563 6201 2734 2084 306 21.3k
Edwin K. Silverman 18345 9447 1530 3740 440 26.1k
Stephen I. Rennard 19767 11938 2191 6743 537 34.5k
Robert A. Wise 15681 10149 281 3174 832 34.6k
Alberto Papi 13431 11989 549 1904 421 21.6k
Guy Brusselle 11972 11692 914 2547 389 21.9k
Leonardo M. Fabbri 26974 18453 593 2950 434 38.1k
Masaharu Nishimura 16400 6920 835 3452 609 25.7k
Don D. Sin 23913 11988 710 2995 466 32.4k

All Works

Loading papers...

Rankless by CCL
2026